NCI begins rewrite of cancer center grant guidelines; will allow clinical investigator support. Goal is to implement P30-P50 working group recommendations, simplify guidelines, Karen Antman tells advisory board.
NCI considers allowing some centers to opt out of site visits.
Board of Scientific Advisors discussion: Are peer reviewers correctly interpreting the guidelines?
Also in this 8-page issue: John Mendelsohn selected for BMS award. National Coalition for Cancer Survivorship and The Wellness Community begin advocacy initiative.
Business & Regulatory Report March edition (8 pages) included.
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”
